First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma

Pérez de Llano, L. A; Cosío, B. G; Lobato Astiárraga, I; Soto Campos, G; Tejedor Alonso, M. A; Marina Malanda, N; Padilla Galo, A; Urrutia Landa, I; Michel de la Rosa, F. J; García-Moguel, I.
J. investig. allergol. clin. immunol ; 33(3): 220-222, 2023. tab
Artículo en Inglés | IBECS (España) | ID: ibc-221945

Documentos relacionados

  1. Real-life experience after 3 months with tezepelumab before marketing approval.
  2. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study.
  3. In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control.
  4. In severe, uncontrolled asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y.
  5. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study.
  6. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.
  7. Clinical profile of severe asthmatics receiving biological treatment: see behind the scenes.
  8. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience.
  9. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
  10. Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.